Sam Chun Dang Pharm Q1 2026 Strong Results, Expanded Biosimilar and Oral Semaglutide Contracts

Consolidated revenue KRW 64.9bn (up 28% YoY), operating profit KRW 5.4bn, net profit KRW 6.9bn.
Biosimilar SCD411 (aflibercept) received market approvals in Canada, Europe, Korea, UK and exports started.
Oral semaglutide generics (Rybelsus/Wegovy) licensed in US (total deal value $100mn), Europe (€30mn), Japan.
Oral insulin phase 1/2 clinical trial application submitted to EMA.
Total assets KRW 573.1bn, equity KRW 394.5bn, cash & equivalents KRW 84.2bn (net cash position).
Credit rating maintained at BBB- (stable).
R&D expenses KRW 7.9bn (12.2% of sales), continued capitalization of SCD411 development costs.
10 pending lawsuits (totaling KRW 4.4bn) but management assesses immaterial.